Neeraj Agrawal on Muck Rack

Neeraj Agrawal

Boston
As seen in: Medium, Nature, Wiley Online Library, Nurse Education in Practice, TechCrunch, MDPI, Substack, Firstpost, McKinsey & Company, The National and
Cloud investor @BatteryVentures. Forbes Midas List (2011-21). Co-host #CloudNY CEO conf. @hackdiversity BoD. Views my own, no investment advice intended.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neeraj

Contact Neeraj, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

05.18.26 -- Why Dilution Gets Tricky: The Role Of Measurement Variability

|
By Ramakrishnan Natesan, Jenil R. Patel, Neeraj Agrawal
| Bioprocess Online Verified
Webinar: Simplifying ADC Analysis: Real-Time DAR and Concentration Measurement Without Dilution Unlock faster, safer ADC development with smarter analytics. This Repligen webinar reveals how variable pathlength spectroscopy delivers real-time, accurate DAR and concentration data without dilution. Explore case studies showing reduced variability, minimized handling of potent payloads, and streamlined workflows.
Open in Who Shared Issue with article?

Why Dilution Gets Tricky: The Role of Measurement Variability Original

|
By Ramakrishnan Natesan, Jenil R. Patel, Neeraj Agrawal
| Bioprocess Online Verified
By Ramakrishnan Natesan, Jenil Patel, Neeraj J. Agrawal — Process Development, Amgen Inc. Dilution of pharmaceutical ingredients is a fundamental operation in biopharmaceutical manufacturing, used in applications ranging from buffer preparation to converting high-concentration drug substance (DS) into lower-concentration drug product (DP). It is also routinely performed during sample preparation for analytical testing.
Open in Who Shared View Duplicates (2) Issue with article?

US-Based XCath Raises $30 Million in Series C to Advance Neuro-Endovascular Surgical Robotics

|
By Crescent Enterprises, Neeraj Agrawal
| entarabi.com
US-Based XCath Raises $30 Million in Series C to Advance Neuro-Endovascular Surgical Robotics The funding will support remote robotic interventions for stroke treatment XCath, a US company specializing in neuro-endovascular surgical robotics, has raised $30 million in a Series C funding round, bringing its total capital raised since inception to $92 million. The round was led by UAE-based Crescent Enterprises.
Open in Who Shared Issue with article?
See all 118 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified